Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 4/20 | 0.33 |
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | HTR2B | P41595 | 4/20 | 0.33 |
| ▸ | HTR1A | P08908 | 3/20 | 0.33 |
| ▸ | HTR7 | P34969 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22271919 | 0.90 | HTT (0.32) | ACHECNR2 | |
| SCHEMBL22761232 | 0.90 | ACHE (0.38) | ACHEHTR2AHTR2CPDE4D | |
| SCHEMBL28057669 | 0.87 | TP53 (0.36) | ACHETP53 | |
| SCHEMBL17601999 | 0.86 | ADRA2A (0.41) | ACHEHTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL17601979 | 0.83 | CHRNA7 (0.43) | ACHEHTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL16002508 | 0.83 | HTR1A (0.36) | ACHEHTR2AHTR1APDE4B | |
| SCHEMBL22271831 | 0.83 | ACHE (0.52) | ACHE | |
| SCHEMBL22760876 | 0.82 | ACHE (0.40) | ACHE | |
| SCHEMBL17602025 | 0.81 | ACHE (0.34) | ACHEHTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL17602004 | 0.81 | MAOA (0.35) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385396-A1 | Compond for treatment or prevention of of obesity or diseases related to obesity, and application thereof | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385396-A1 | Compond for treatment or prevention of of obesity or diseases related to obesity, and application thereof | PCSK9, FABP4, GPR119 | ACHE 2644/4885HTR2A 2321/4885HTR2C 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.